PriceTargets.com logo

Rocket Pharmaceuticals - RCKT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $15.47
  • Forecasted Upside: 352.24%
  • Number of Analysts: 18
  • Breakdown:
  • 3 Sell Ratings
  • 7 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$3.42 As of 12/4/2025 05:00 PM ET
▲ +0.08 (2.40%)

This chart shows the closing price for RCKT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Rocket Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RCKT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RCKT

Analyst Price Target is $15.47
▲ +352.24% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for Rocket Pharmaceuticals in the last 3 months. The average price target is $15.47, with a high forecast of $44.00 and a low forecast of $5.00. The average price target represents a 352.24% upside from the last price of $3.42.

This chart shows the closing price for RCKT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 18 contributing investment analysts is to hold stock in Rocket Pharmaceuticals. This rating has held steady since May 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 8 hold ratings
  • 2 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 3 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 3 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/18/2025Bank of AmericaLower TargetBuy ➝ Buy$10.00 ➝ $8.00
11/18/2025JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
11/7/2025WedbushReiterated RatingOutperform$16.00
10/14/2025Chardan CapitalReiterated RatingBuy ➝ Buy$11.00
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/3/2025Leerink PartnersLower TargetMarket Perform ➝ Market Perform$9.00 ➝ $7.00
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
8/20/2025Bank of AmericaUpgradeNeutral ➝ Buy$4.00 ➝ $10.00
8/20/2025Chardan CapitalReiterated RatingBuy ➝ Buy$11.00
8/11/2025Chardan CapitalLower TargetBuy ➝ Buy$12.00 ➝ $11.00
8/8/2025Cantor FitzgeraldLower TargetOverweight ➝ Overweight$10.00 ➝ $8.00
7/25/2025Canaccord Genuity GroupLower TargetBuy ➝ Buy$11.00 ➝ $10.00
7/25/2025Bank of AmericaReiterated RatingBuy ➝ Neutral$9.00 ➝ $4.00
7/24/2025Chardan CapitalLower TargetBuy ➝ Buy$17.00 ➝ $12.00
7/24/2025Needham & Company LLCReiterated RatingHold ➝ Hold
6/17/2025UBS GroupLower TargetBuy ➝ Buy$12.00 ➝ $5.00
6/3/2025Canaccord Genuity GroupLower TargetBuy ➝ Buy$34.00 ➝ $11.00
5/30/2025Evercore ISIDowngradeOutperform ➝ In-Line$5.00
5/28/2025UBS GroupReiterated RatingBuy ➝ Buy
5/28/2025JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral
5/28/2025Bank of AmericaLower TargetBuy ➝ Buy$32.00 ➝ $9.00
5/28/2025BMO Capital MarketsLower TargetOutperform ➝ Outperform$30.00 ➝ $8.00
5/28/2025ScotiabankLower TargetSector Outperform ➝ Sector Outperform$51.00 ➝ $19.00
5/28/2025The Goldman Sachs GroupDowngradeNeutral ➝ Sell
5/28/2025Leerink PartnersReiterated RatingOutperform ➝ Market Perform$37.00 ➝ $8.00
5/28/2025Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$7.00
5/28/2025Chardan CapitalLower TargetBuy ➝ Buy$46.00 ➝ $17.00
5/28/2025Jefferies Financial GroupReiterated RatingBuy ➝ Hold
5/27/2025Leerink PartnrsDowngradeStrong-Buy ➝ Hold
5/27/2025TD CowenReiterated RatingBuy ➝ Hold
5/27/2025Needham & Company LLCDowngradeBuy ➝ Hold$42.00
5/16/2025Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$20.00 ➝ $30.00
5/16/2025WedbushReiterated RatingOutperform ➝ Outperform$32.00 ➝ $32.00
5/16/2025Chardan CapitalBoost TargetBuy ➝ Buy$45.00 ➝ $46.00
5/12/2025ScotiabankLower TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $51.00
5/12/2025Canaccord Genuity GroupLower TargetBuy ➝ Buy$36.00 ➝ $34.00
5/9/2025Chardan CapitalLower TargetBuy ➝ Buy$54.00 ➝ $45.00
5/9/2025JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$45.00 ➝ $44.00
5/9/2025The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$15.00 ➝ $13.00
4/9/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
3/12/2025BMO Capital MarketsInitiated CoverageOutperform$50.00
3/3/2025The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$29.00 ➝ $15.00
3/3/2025ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$51.00 ➝ $52.00
3/3/2025Canaccord Genuity GroupLower TargetBuy ➝ Buy$39.00 ➝ $36.00
2/28/2025Chardan CapitalLower TargetBuy ➝ Buy$62.00 ➝ $54.00
2/28/2025Needham & Company LLCLower TargetBuy ➝ Buy$52.00 ➝ $42.00
12/30/2024WedbushInitiated CoverageOutperform$32.00
12/18/2024Jefferies Financial GroupInitiated CoverageBuy$29.00
11/19/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$39.00 ➝ $39.00
11/19/2024Leerink PartnersLower TargetOutperform ➝ Outperform$46.00 ➝ $44.00
11/19/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00 ➝ $65.00
11/19/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$52.00 ➝ $52.00
11/18/2024Chardan CapitalReiterated RatingBuy ➝ Buy$62.00 ➝ $62.00
11/11/2024Chardan CapitalReiterated RatingBuy ➝ Buy$62.00 ➝ $62.00
11/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$52.00 ➝ $52.00
10/16/2024ScotiabankInitiated CoverageSector Outperform$50.00
9/30/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
9/17/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$52.00 ➝ $52.00
8/6/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$50.00 ➝ $54.00
8/6/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00 ➝ $65.00
8/6/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$52.00 ➝ $52.00
8/6/2024Chardan CapitalReiterated RatingBuy ➝ Buy$62.00 ➝ $62.00
7/3/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$49.00 ➝ $40.00
6/28/2024Chardan CapitalReiterated RatingBuy ➝ Buy$62.00 ➝ $62.00
6/28/2024Needham & Company LLCLower TargetBuy ➝ Buy$53.00 ➝ $52.00
6/3/2024William BlairReiterated RatingOutperform
5/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$53.00
4/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$53.00
4/2/2024The Goldman Sachs GroupInitiated CoverageNeutral$39.00
3/1/2024UBS GroupLower TargetBuy ➝ Buy$56.00 ➝ $54.00
2/27/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$55.00 ➝ $50.00
2/27/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00
2/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$53.00
1/31/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00
12/26/2023Lifesci CapitalReiterated RatingOutperform
11/7/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$53.00
10/24/2023Cantor FitzgeraldInitiated CoverageOverweight$65.00
9/13/2023Stifel NicolausReiterated RatingBuy ➝ Buy$48.00
9/13/2023Needham & Company LLCLower TargetBuy ➝ Buy$60.00 ➝ $53.00
8/11/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$49.00 ➝ $47.00
8/11/2023Chardan CapitalReiterated RatingBuy ➝ Buy$61.00
8/10/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00
8/10/2023Stifel NicolausLower TargetBuy ➝ Buy$53.00 ➝ $48.00
5/5/2023Chardan CapitalLower Target$63.00 ➝ $61.00
4/19/2023Needham & Company LLCReiterated RatingBuy$60.00
3/22/2023William BlairReiterated RatingOutperform
3/1/2023Chardan CapitalLower TargetBuy$65.00 ➝ $63.00
2/28/2023Needham & Company LLCReiterated RatingBuy$60.00
2/1/2023Morgan StanleyInitiated CoverageOverweight$45.00
1/23/2023Leerink PartnersLower TargetOutperform$50.00 ➝ $49.00
12/23/2022Bank of AmericaLower TargetBuy$38.00 ➝ $35.00
12/22/2022Leerink PartnersLower TargetOutperform$54.00 ➝ $50.00
12/6/2022Leerink PartnersLower TargetOutperform$56.00 ➝ $54.00
11/8/2022Canaccord Genuity GroupInitiated CoverageBuy$53.00
11/7/2022Canaccord Genuity GroupInitiated CoverageBuy$53.00
11/4/2022Needham & Company LLCLower TargetBuy$62.00 ➝ $60.00
11/1/2022BTIG ResearchInitiated CoverageBuy$35.00
10/3/2022Raymond James FinancialBoost TargetOutperform$24.00 ➝ $34.00
9/30/2022Leerink PartnersLower TargetOutperform$65.00 ➝ $60.00
9/30/2022Chardan CapitalBoost TargetBuy$62.00 ➝ $65.00
9/30/2022Evercore ISIBoost TargetOutperform$65.00 ➝ $75.00
9/27/2022UBS GroupLower TargetBuy$68.00 ➝ $62.00
8/9/2022Raymond James FinancialBoost TargetOutperform$22.00 ➝ $24.00
7/8/2022Raymond James FinancialInitiated CoverageOutperform
7/6/2022Leerink PartnersLower TargetOutperform$66.00 ➝ $64.00
5/20/2022Leerink PartnersBoost TargetOutperform$64.00 ➝ $66.00
5/19/2022Chardan CapitalBoost TargetBuy$60.00 ➝ $62.00
5/19/2022Stifel NicolausBoost Target$63.00 ➝ $67.00
5/17/2022Needham & Company LLCLower TargetBuy$75.00 ➝ $62.00
5/5/2022William BlairReiterated RatingOutperform
4/12/2022Needham & Company LLCReiterated RatingBuy$75.00
2/24/2022Leerink PartnersBoost TargetOutperform$62.00 ➝ $64.00
12/15/2021Chardan CapitalBoost TargetBuy$56.00 ➝ $60.00
10/24/2021Lifesci CapitalReiterated RatingOutperform
10/24/2021Leerink PartnersReiterated RatingBuy
9/19/2021Leerink PartnersReiterated RatingBuy
9/7/2021Chardan CapitalReiterated RatingBuy
8/19/2021Leerink PartnersReiterated RatingBuy
8/10/2021Chardan CapitalReiterated RatingBuy$56.00
8/10/2021Needham & Company LLCReiterated RatingBuy$75.00
8/10/2021Leerink PartnersLower TargetOutperform$66.00 ➝ $62.00
8/10/2021William BlairReiterated RatingBuy
7/7/2021Chardan CapitalReiterated RatingBuy
4/1/2021Leerink PartnersBoost TargetOutperform$61.00 ➝ $66.00
3/1/2021Stifel NicolausInitiated CoverageBuy$64.00
2/18/2021Needham & Company LLCInitiated CoverageBuy$75.00
1/4/2021Piper SandlerBoost Target$60.00 ➝ $80.00
12/15/2020UBS GroupInitiated CoverageBuy$75.00
12/10/2020Evercore ISIBoost TargetOutperform$65.00 ➝ $100.00
12/8/2020Chardan CapitalBoost TargetPositive ➝ Buy$35.00 ➝ $46.00
12/8/2020Piper SandlerBoost TargetOverweight$35.00 ➝ $50.00
12/8/2020OppenheimerDowngradeOutperform ➝ Market Perform
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.63 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 7 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 7 very positive mentions
  • 115 positive mentions
  • 6 negative mentions
  • 6 very negative mentions
Mentions as of
7/7/2025
  • 8 very positive mentions
  • 139 positive mentions
  • 8 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 22 very positive mentions
  • 32 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
9/5/2025
  • 6 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 5 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 5 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Rocket Pharmaceuticals logo
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
Read More

Today's Range

Now: $3.42
Low: $3.32
High: $3.46

50 Day Range

MA: $3.41
Low: $2.84
High: $4.27

52 Week Range

Now: $3.42
Low: $2.19
High: $15.00

Volume

1,064,761 shs

Average Volume

1,988,659 shs

Market Capitalization

$370.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Rocket Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on Rocket Pharmaceuticals in the last year: Bank of America Corporation, BMO Capital Markets, Canaccord Genuity Group Inc., Cantor Fitzgerald, Chardan Capital, Evercore ISI, Jefferies Financial Group Inc., JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Morgan Stanley, Needham & Company LLC, Scotiabank, TD Cowen, The Goldman Sachs Group, Inc., UBS Group AG, Wedbush, and Weiss Ratings.
View the latest analyst ratings for RCKT.

What is the current price target for Rocket Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Rocket Pharmaceuticals in the last year. Their average twelve-month price target is $15.47, suggesting a possible upside of 352.2%. JPMorgan Chase & Co. has the highest price target set, predicting RCKT will reach $44.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $5.00 for Rocket Pharmaceuticals in the next year.
View the latest price targets for RCKT.

What is the current consensus analyst rating for Rocket Pharmaceuticals?

Rocket Pharmaceuticals currently has 3 sell ratings, 7 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in RCKT, but not buy more shares or sell existing shares.
View the latest ratings for RCKT.

What other companies compete with Rocket Pharmaceuticals?

Other companies that are similar to Rocket Pharmaceuticals include Nurix Therapeutics, Ardelyx, Precigen, Urogen Pharma and Oruka Therapeutics. Learn More about companies similar to Rocket Pharmaceuticals.

How do I contact Rocket Pharmaceuticals' investor relations team?

Rocket Pharmaceuticals' physical mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The biotechnology company's listed phone number is (609) 659-8001 and its investor relations email address is [email protected]. The official website for Rocket Pharmaceuticals is www.rocketpharma.com. Learn More about contacing Rocket Pharmaceuticals investor relations.